Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting

 描述（由申请人提供）：精准医学可以通过在正确的时间为正确的患者确定正确的药物来影响癌症的治疗。然而，当前的前端病理学工具不足以用于当今复杂的功能基因组测试。为了改善患者的治疗效果，我们提出了一种创新技术，表达显微切割（xMD），该技术利用标准免疫组织化学方法从异质组织切片中轻松快速地分离纯肿瘤细胞群。在我们的提案中，我们的目标是通过评估解剖效率、特异性和可重复性，在临床上验证xMD技术对常见肿瘤类型的作用，并为xMD过程建立标准操作规程（SOP）。我们还将评价回收的DNA、RNA和蛋白质的质量，并评估xMD对测定结果的影响。最后，我们将研究一组肺癌标本，以评估xMD的稳健性，并生成一份详细说明每个患者标本分子特征的综合患者报告。

 DESCRIPTION (provided by applicant): Precision medicine can impact the treatment of cancer by identifying the right drug at the right time for the right patient. However, current fron-end pathology tools are insufficient for today's sophisticated functional genomic tests. In order t improve patient outcomes, we propose to advance an innovative technology, Expression Microdissection (xMD) that utilizes standard immunohistochemistry to easily and rapidly isolate pure tumor cell populations from heterogeneous tissue sections. In our proposal, we aim to clinically validate xMD technology on common tumor types by assessing dissection efficiency, specificity, and reproducibility, and to establish standard operating procedures (SOPs) for the xMD process. We will also evaluate the quality of the recovered DNA, RNA and protein and assess the effect of xMD on assay results. Finally, we will study a set of lung cancer specimens to evaluate the robustness of xMD and generate a comprehensive patient report detailing the molecular profile of each patient specimen.